Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
Condition(s) studied
Investigational drug(s) / intervention(s)
LB-102 (50 mg tablet): LB-102 oral tablet given for six weeks
LB-102 (100 mg tablet): LB-102 oral tablet given for six weeks
Placebo: Placebo tablet given orally for six weeks
Study summary
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.
Eligibility
Primary outcome measure(s)
- Change from baseline to Week 6 on the Positive and Negative Syndrome Scale — 6 weeks
Determine whether LB-102, demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo: increase in scale indicates worsening while a decrease in the scale likely indicates a response to treatment
Trial sites (13)
| Facility | City | Region | Status |
|---|---|---|---|
| Pillar Clinical Research | Bentonville | Arkansas | Recruiting |
| Pillar Clinical Research | Little Rock | Arkansas | Recruiting |
| Woodland International Research Group | Little Rock | Arkansas | Recruiting |
| ProScience Research Group | Culver City | California | Recruiting |
| CenExel | Garden Grove | California | Recruiting |
| Synergy San Diego | Lemon Grove | California | Recruiting |
| Clinical Innovations, Inc. | Riverside | California | Recruiting |
| Health Synergy Clinical Research | Boynton Beach | Florida | Recruiting |
| Innovative Clinical Research | Miami Lakes | Florida | Recruiting |
| Accelerated Clinical Trial | Snellville | Georgia | Recruiting |
| Pillar Clinical Research | Chicago | Illinois | Recruiting |
| Arch Clinical Trials | St Louis | Missouri | Recruiting |
| Neuro-Behavioral Clinical Research | North Canton | Ohio | Recruiting |
More LB Pharmaceuticals Inc. trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07363577 on ClinicalTrials.gov ↗ ← All trials in the USA